David R. Epstein, Director at Rubius Therapeutics, Inc. (RUBY), bought 5,000 shares at $3.76 ($19K) on 2020-03-17, disclosed to the SEC on 2020-03-19.
Open-market purchase of $19k RUBY by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Something here stands out, but not much.
| Filing → |
| TEM | SELL | 2026-06-03 | $12K | — | Filing → |
| TEM | SELL | 2026-03-04 | $13K | — | Filing → |
| TEM | SELL | 2026-02-04 | $22K | — | Filing → |